10-Q: Spruce Biosciences Faces Delisting Amidst Financial Uncertainty, Focuses on Sanfilippo Syndrome Treatment

Spruce Biosciences reports Q1 2025 results, highlighting a shift towards tralesinidase alfa (TA-ERT) development for Sanfilippo Syndrome Type B amidst delisting concerns and substantial doubt about its ability to continue as a going concern.

Summary

• Spruce Biosciences, a late-stage biopharmaceutical company, reported a net loss of $14.0 million for the three months ended March 31, 2025, and used $12.7 million of cash in operations.
• As of March 31, 2025, the company had cash and cash equivalents of $25.6 million and an accumulated deficit of $264.3 million.
• The company is shifting its focus to the development of tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B and plans to submit a BLA in the first half of 2026.
• Spruce Biosciences faces delisting from Nasdaq due to non-compliance with the minimum bid price requirement, and its common stock began trading on the OTC Pink Marketplace on April 29, 2025.
• The company implemented a workforce reduction of 55% on April 21, 2025, to prioritize TA-ERT development, expecting to incur approximately $0.9 million in cash charges.
• There is substantial doubt about the company's ability to continue as a going concern for at least 12 months following the issuance date of the financial statements without alternative financing or strategic alternatives.
• The company is pursuing regulatory approval of TA-ERT in patients with MPSIIIB and advancing clinical development of tildacerfont in MDD.
• Collaboration revenue for the three months ended March 31, 2024, was $2.0 million under the Kaken License Agreement, with no collaboration revenue for the same period in 2025.
• Research and development expenses increased by $0.5 million, primarily related to the acquisition of SPR202, offset by decreased clinical development activities related to the discontinuation of the tildacerfont CAH development program.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with delisting risks and going concern doubts, overshadowing the potential of the company's pipeline.

Positives

• The company is focusing on the development of TA-ERT, which has shown promising results in clinical studies for MPSIIIB.
• The FDA has confirmed that HS-NRE is deemed to be a biomarker reasonably likely to predict clinical benefit and could serve as a basis for accelerated approval.
• The company has a strategic partnership with HMNC to investigate the potential of tildacerfont in MDD patients.
• The company is advancing pre-clinical and clinical development of SPR202 in CAH and SPR204 in PBH.

Negatives

• The company has incurred significant net losses since its inception and anticipates continuing to do so.
• There is substantial doubt about the company's ability to continue as a going concern without additional financing.
• The company is facing delisting from Nasdaq due to non-compliance with the minimum bid price requirement.
• The company implemented a workforce reduction of 55% to prioritize TA-ERT development.
• The company has no products approved for commercial sale and has not generated any product revenue to date.

Risks

• The company's clinical trials may fail to adequately demonstrate the safety and efficacy of its product candidates.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company is dependent on intellectual property licensed from others, the termination of which could result in the loss of significant rights.
• The company relies on third parties to conduct its clinical trials and manufacture its drug supplies.
• The company may be unable to obtain and maintain sufficient intellectual property protection for its product candidates.
• Unfavorable U.S. and global economic and geopolitical conditions could adversely affect the company's business.
• The company is highly dependent on its key personnel, and if it is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future and will need to raise substantial additional capital to fund its operations and debt obligations.

Management Comments

• Management believes that early intervention with TA-ERT stabilizes cognitive decline in patients with MPSIIIB.
• Management intends to submit a plan to regain compliance to that effect to the Hearings Panel as part of the hearing process; however, there can be no assurances that the Hearings Panel will grant any request for continued listing or that the Company will be able to regain compliance with the applicable listing criteria within the period of time that may be granted by the Hearings Panel.

Industry Context

The biopharmaceutical industry is characterized by intense competition and rapid innovation, and Spruce Biosciences faces significant competition from other biotechnology and pharmaceutical companies.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards or benchmarks.
• The document does not list specific comparable companies, projects, or results.

Related Party Transactions

• Effective December 20, 2024, Kirk Ways, M.D., a member of the board of the directors, began serving as the Company's interim Chief Medical Officer pursuant to a consulting agreement, with compensation expense of $0.3 million recognized during the three months ended March 31, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of further stock price decline.
• Employees experienced a 55% workforce reduction.
• Patients with MPSIIIB may benefit from the development of TA-ERT, but its availability is uncertain.
• The company's creditors face increased risk due to the company's financial instability.

Next Steps

• The company intends to submit a BLA for TA-ERT for the treatment of MPSIIIB in the first half of 2026.
• The company intends to submit a plan to regain compliance to that effect to the Hearings Panel as part of the hearing process.
• The company will continue to advance clinical development of tildacerfont in MDD and pre-clinical and clinical development of SPR202 in CAH and SPR204 in PBH.

Key Dates

Keywords

Tralesinidase alfa, Tildacerfont, Sanfilippo Syndrome Type B, MPSIIIB, Clinical trials, Regulatory approval, Delisting, Biopharmaceutical, Financial results, Going concern